Astellas Sees Further FDA Action On Prograf MR In Early 2008
This article was originally published in PharmAsia News
Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1
You may also be interested in...
Action comes one year after the company withdrew an NDA for the antibiotic in the U.S.
Announcement comes just ahead of an FDA advisory committee meeting to discuss EPO products.
Firm will meet with FDA to get combination therapy for prevention of kidney transplant rejection approved.